Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 1999

View Archived Issues

ImmGenics and Genzyme enter collaboration agreement to use SLAM technology

Gene Logic and UCB Research enter allergy and asthma gene expression agreement

Soluble Tat peptide analogues, HIV replication inhibitors, available for licensing from NIH

Icos highlights clinical results from product development program

Takeda to collaborate in the development of Dainippon's candidate antidiabetic

Genzyme Molecular Oncology licenses antisense cancer rights to Hybridon

Zambon and Sheffield initiate MSI albuterol trial for treatment of pediatric asthma

Isis and RPR establish collaboration for antisense target validation

Yale study will evaluate memantine's ability to prevent vision loss in glaucoma patients

Cytokine inhibitors from Ortho-McNeil and methods of treating rheumatoid arthritis, etc.

New muscarinic antagonists developed at Roche

Shionogi's new immunosuppressant/antiallergic compounds

Promising anti-HIV drug candidate strongly inhibits T-tropic and T/M-tropic infections in SCID mice

In vivo efficacy and CNS toxicity of T-3811ME described at major congress

Lilly's PTH analogue LY-333334 featured at this week's ASBMR meeting

BMS seeks FDA approval for novel oral antidiabetic drug

Novel semisynthetic pleuromutilins with potential as topical antibacterial agents

Scotia seeks FDA approval for Foscan PDT

Novo Nordisk takes a different tack in search of greater strength

Profile of new small-molecule CCR5 antagonist from Takeda detailed further at ICAAC

Geranylgeranyltransferase inhibition as a mechanism for specifically inhibiting bone resorption

Medco initiates phase II trial of MRE-0470

Compound from Streptomyces inhibits bone resorption, induces apoptosis in osteoclasts in vitro

Glaxo Wellcome launches lamivudine in China for treatment of chronic HBV

ICAAC news: anti-HIV-1 activity and enzyme/drug interactions of (+)-calanolide A

British Biotech moves novel rheumatoid arthritis treatment into development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...